Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aileron Therapeutics Inc (NQ: ALRN )

1.930 USD -0.010 (-0.52%)
Streaming Delayed Price Updated: 12:34 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aileron Therapeutics Inc

< Previous 1 2 Next >
Thinking about buying stock in Nio, Zomedica, Transenterix, Aileron Therapeutics, or BioNano Genomics?
InvestorsObserver issues critical PriceWatch Alerts for NIO, ZOM, TRXC, ALRN, and BNGO. 
From PR Newswire
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investm
From GlobeNewswire News Releases
Aileron Therapeutics Announces $35.9 Million Registered Direct Offering
From GlobeNewswire News Releases
Thinking about buying stock in Aileron Therapeutics, Check Cap, Jaguar Health, Clearside Biomedical, or Gritstone Oncology?
InvestorsObserver issues critical PriceWatch Alerts for ALRN, CHEK, JAGX, CLSD, and GRTS. 
From PR Newswire
Thinking about buying stock in Pfizer, Senseonics Holdings, AIM ImmunoTech, Aileron Therapeutics, or Microvision?
InvestorsObserver issues critical PriceWatch Alerts for PFE, SENS, AIM, ALRN, and MVIS. 
From PR Newswire
Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities
From GlobeNewswire News Releases
Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
From GlobeNewswire News Releases
Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
From GlobeNewswire News Releases
Thinking about buying stock in Staffing 360 Solutions, IBM, Selecta Biosciences, 3M, or Aileron Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for STAF, IBM, SELB, MMM, and ALRN. 
From PR Newswire
Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium
From GlobeNewswire News Releases
Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio?
InvestorsObserver issues critical PriceWatch Alerts for AKBA, ALRN, RIOT, PLUG, and TBIO. 
From PR Newswire
Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium
From GlobeNewswire News Releases
Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
From GlobeNewswire News Releases
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
From GlobeNewswire News Releases
Thinking about buying stock in Beam Therapeutics, Digital Turbine, Arbutus Biopharma, Aileron Therapeutics, or Snap Inc?
InvestorsObserver issues critical PriceWatch Alerts for BEAM, APPS, ABUS, ALRN, and SNAP. 
From PR Newswire
Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August
From GlobeNewswire News Releases
Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924
From GlobeNewswire News Releases
Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotec
From GlobeNewswire News Releases
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
From GlobeNewswire News Releases
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Aileron Therapeutics Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Thinking about buying stock in Ovid Therapeutics, Celsion Corp, Aileron Therapeutics, Cronos Group, or Bank of America?
InvestorsObserver issues critical PriceWatch Alerts for OVID, CLSN, ALRN, CRON, and BAC. 
From PR Newswire
Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer
From GlobeNewswire News Releases
Thinking about buying stock in PhaseBio Pharmaceuticals, Aileron Therapeutics, JetBlue Airways, Aurora Cannabis, or Remark Holdings?
InvestorsObserver issues critical PriceWatch Alerts for PHAS, ALRN, JBLU, ACB, and MARK. 
From PR Newswire
Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent
From GlobeNewswire News Releases
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020
From GlobeNewswire News Releases
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
From GlobeNewswire News Releases
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer
From GlobeNewswire News Releases
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.